Healthcare groups are reacting to Novo Nordisk’s recent petition to the FDA to prevent compounding pharmacies from producing unapproved — and often cheaper — versions of weight loss injection Wegovy and diabetes treatment Ozempic.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
